LU92759I2 - Vorapaxar ou son sel solvat pharmacologiquement admissible - Google Patents

Vorapaxar ou son sel solvat pharmacologiquement admissible Download PDF

Info

Publication number
LU92759I2
LU92759I2 LU92759C LU92759C LU92759I2 LU 92759 I2 LU92759 I2 LU 92759I2 LU 92759 C LU92759 C LU 92759C LU 92759 C LU92759 C LU 92759C LU 92759 I2 LU92759 I2 LU 92759I2
Authority
LU
Luxembourg
Prior art keywords
pharmacologiquement
solvat
vorapaxar
admissible
son sel
Prior art date
Application number
LU92759C
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29250954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92759(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of LU92759I2 publication Critical patent/LU92759I2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU92759C 2002-04-16 2015-06-29 Vorapaxar ou son sel solvat pharmacologiquement admissible LU92759I2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37307202P 2002-04-16 2002-04-16

Publications (1)

Publication Number Publication Date
LU92759I2 true LU92759I2 (en) 2015-08-31

Family

ID=29250954

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92759C LU92759I2 (en) 2002-04-16 2015-06-29 Vorapaxar ou son sel solvat pharmacologiquement admissible

Country Status (33)

Country Link
US (3) US7304078B2 (pl)
EP (5) EP1860106B1 (pl)
JP (2) JP4558331B2 (pl)
KR (1) KR101026929B1 (pl)
CN (1) CN1659162B (pl)
AR (1) AR039570A1 (pl)
AT (3) ATE455774T1 (pl)
AU (1) AU2003221932B2 (pl)
BR (1) BRPI0309309B8 (pl)
CA (1) CA2482858C (pl)
CY (3) CY1107184T1 (pl)
DE (3) DE60335679D1 (pl)
DK (2) DK2065384T3 (pl)
EC (1) ECSP045368A (pl)
ES (3) ES2338171T3 (pl)
FR (1) FR15C0047I2 (pl)
IL (1) IL164585A (pl)
LT (1) LTC1495018I2 (pl)
LU (1) LU92759I2 (pl)
MX (1) MXPA04010308A (pl)
MY (1) MY144040A (pl)
NL (1) NL300746I2 (pl)
NO (2) NO330500B1 (pl)
NZ (2) NZ575139A (pl)
PE (1) PE20040412A1 (pl)
PL (1) PL214718B1 (pl)
PT (2) PT1495018E (pl)
RU (2) RU2329264C9 (pl)
SG (1) SG164279A1 (pl)
SI (2) SI2065384T1 (pl)
TW (1) TWI343919B (pl)
WO (1) WO2003089428A1 (pl)
ZA (1) ZA200408342B (pl)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US7442712B2 (en) * 2004-05-28 2008-10-28 Schering Corporation Constrained himbacine analogs as thrombin receptor antagonists
AU2005294265A1 (en) * 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
EP1848683A2 (en) * 2005-01-14 2007-10-31 Schering Corporation Preparation of chiral propargylic alcohol and ester intermediates of himbacine analogs
US7772276B2 (en) * 2005-01-14 2010-08-10 Schering Corporation Exo-selective synthesis of himbacine analogs
EP2206697B1 (en) * 2005-01-14 2011-10-26 Schering Corporation Exo- and diastereo-selective syntheses of himbacine analogs
US7541471B2 (en) * 2005-01-14 2009-06-02 Schering Corporation Synthesis of himbacine analogs
SG158885A1 (en) * 2005-01-14 2010-02-26 Schering Corp Synthesis of himbacine analogs
AR053566A1 (es) 2005-03-31 2007-05-09 Schering Corp Compuestos espiriciclicos antagonistas de los receptores de trombina
WO2007075808A2 (en) * 2005-12-20 2007-07-05 Schering Corporation Methods for preventing and/or treating a cell proliferative disorder
BRPI0620641A2 (pt) * 2005-12-22 2011-11-16 Schering Corp usos de compostos antagonistas de receptor de trombina na profilaxia de complicações de cirurgia cardiopulmonar
TW200812619A (en) * 2006-04-06 2008-03-16 Schering Corp TRA combination therapies
CA2650404A1 (en) 2006-04-13 2007-10-25 Schering Corporation Fused ring thrombin receptor antagonists
US8022088B2 (en) * 2006-06-29 2011-09-20 Schering Corporation Substituted bicyclic and tricyclic thrombin receptor antagonists
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
DE102006036023A1 (de) 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
AU2007305269A1 (en) * 2006-10-04 2008-04-10 Schering Corporation Bicyclic and tricyclic derivatives as thrombin receptor antagonists
EP2078012A2 (en) * 2006-10-04 2009-07-15 Schering Corporation Thrombin receptor antagonists based on the modified tricyclic unit of himbacine
JP2010513516A (ja) * 2006-12-22 2010-04-30 シェーリング コーポレイション 固形剤の湿式顆粒化処方物中の崩壊促進剤
JP2010522169A (ja) * 2007-03-23 2010-07-01 シェーリング コーポレイション トロンビン受容体アンタゴニストの使用による、経皮的インターベンション後の有害事象の低減
BRPI0907487A2 (pt) 2008-02-05 2015-07-14 Sanofi Aventis Sais de triazólio como inibidores de par1, produção dos mesmos e uso como medicamentos
RU2499797C2 (ru) 2008-02-05 2013-11-27 Санофи-Авентис Триазолопиридазины в качестве ингибиторов par1, их получение и применение в качестве лекарственных средств
WO2009124103A2 (en) * 2008-04-02 2009-10-08 Schering Corporation Combination therapies comprising par1 antagonists with par4 antagonists
CA2724430A1 (en) 2008-05-19 2009-11-26 Schering Corporation Heterocyclic compounds as factor ixa inhibitors
PT2438060E (pt) * 2009-06-04 2013-12-16 Merck Sharp & Dohme Metabolito ativo de um antagonista do recetor da trombina
AU2010259003A1 (en) 2009-06-08 2011-11-10 Merck Sharp & Dohme Corp. A thrombin receptor antagonist and clopidogrel fixed dose tablet
AR077695A1 (es) 2009-08-04 2011-09-14 Schering Corp Derivados de pirimidina como inhibidores del factor ixa
EP2558462B1 (de) 2010-04-16 2014-10-22 Sanofi Pyridyl-vinyl-pyrazolo-chinoline als par1-inhibitoren
WO2011128421A1 (de) 2010-04-16 2011-10-20 Sanofi Trizyklische pyridyl-vinyl-pyrrole als par1-inhibitoren
KR101303348B1 (ko) 2010-06-25 2013-09-03 한국화학연구원 트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물
WO2013134012A1 (en) 2012-03-06 2013-09-12 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists
WO2015013083A1 (en) * 2013-07-22 2015-01-29 Merck Sharp & Dohme Corp. Co-crystal of the par-1 receptor antagonist vorapaxar and aspirin
WO2015026693A1 (en) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives
US20160200715A1 (en) 2013-08-22 2016-07-14 Merck Sharp & Dohme Corp. Preparation and use of 7a-heterocycle substituted- 6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
EP3035928B1 (en) * 2013-08-22 2023-10-18 Merck Sharp & Dohme LLC 3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives
FR3014693B1 (fr) 2013-12-16 2016-01-08 Pf Medicament Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
WO2015160636A1 (en) 2014-04-16 2015-10-22 Merck Sharp & Dohme Corp. Factor ixa inhibitors
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105985303B (zh) * 2015-02-13 2020-08-14 上海彩迩文生化科技有限公司 抗凝血剂的制备方法、中间体及其制备方法
CN106478608A (zh) * 2015-09-01 2017-03-08 博瑞生物医药（苏州）股份有限公司 沃拉帕沙的硫酸盐的结晶多晶型物
CN106749201A (zh) * 2015-11-25 2017-05-31 博瑞生物医药（苏州）股份有限公司 一种沃拉帕沙及其中间体的制备方法
TR201601548A2 (tr) * 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
WO2017134200A1 (en) * 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of vorapaxar and metoprolol
TW201738221A (zh) * 2016-04-22 2017-11-01 Jiangsu Tasly Diyi Pharmaceutical Co Ltd 新的喜巴辛類似物、其藥物組合物及其在醫藥中的應用
CN106236779A (zh) * 2016-08-22 2016-12-21 孔五 一种脐带血富血小板血浆prp的制备方法
FR3090317B1 (fr) 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110407819B (zh) * 2019-08-02 2020-06-26 牡丹江医学院 一种作为预防外科手术并发症的凝血酶受体拮抗剂
US20210113536A1 (en) * 2019-10-21 2021-04-22 United States Government as Represented by the Department of Veteran Affairs Methods and compositions for detecting and treating venous thromboembolism
FR3109089B1 (fr) 2020-04-08 2023-04-14 Cvasthera Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
CN116133660B (zh) 2020-07-22 2025-05-02 詹森药业有限公司 可用作因子XIa抑制剂的化合物
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
US12286429B2 (en) 2021-07-22 2025-04-29 Janssen Pharmaceutica Nv 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors
FR3134314A1 (fr) 2022-04-08 2023-10-13 Cvasthera Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
TW197435B (pl) * 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
GB9102862D0 (en) * 1991-02-11 1991-03-27 Erba Carlo Spa N-imidazolyl derivatives of substituted or alkoxymino tetrahydronaphthalenes and chromans
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5576328A (en) 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
CO4990946A1 (es) * 1997-11-25 2000-12-26 Schering Corp Antagonistas del receptor de trombina
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
JP4642318B2 (ja) 2000-06-15 2011-03-02 シェーリング コーポレイション トロンビンレセプターアンタゴニスト
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
ATE525378T1 (de) 2001-10-18 2011-10-15 Schering Corp Himbacinanaloga als thrombinrezeptorantagonisten

Also Published As

Publication number Publication date
EP1495018B3 (en) 2011-03-16
EP1860106B1 (en) 2010-01-20
DK2065384T3 (da) 2011-05-02
EP1982984B1 (en) 2013-02-13
DK1495018T3 (da) 2008-02-18
JP2005528406A (ja) 2005-09-22
PL373332A1 (pl) 2005-08-22
NO2015016I1 (no) 2015-07-20
ZA200408342B (en) 2006-05-31
KR101026929B1 (ko) 2011-04-04
PT1495018E (pt) 2008-02-19
PE20040412A1 (es) 2004-07-12
LTC1495018I2 (lt) 2017-04-10
DE60317493T3 (de) 2018-07-12
PL214718B1 (pl) 2013-09-30
IL164585A (en) 2010-11-30
AR039570A1 (es) 2005-02-23
PT2065384E (pt) 2011-03-16
EP1982984A2 (en) 2008-10-22
HK1070887A1 (en) 2005-06-30
EP1860106A1 (en) 2007-11-28
EP1495018A1 (en) 2005-01-12
ATE455774T1 (de) 2010-02-15
RU2008106401A (ru) 2009-08-27
MY144040A (en) 2011-07-29
NZ575139A (en) 2010-08-27
NO2015016I2 (no) 2015-07-09
AU2003221932B2 (en) 2007-11-22
NZ535880A (en) 2007-11-30
NO20044963L (no) 2004-11-15
US20070270439A1 (en) 2007-11-22
BR0309309A (pt) 2005-02-15
ATE378330T1 (de) 2007-11-15
EP2062890A1 (en) 2009-05-27
HK1129893A1 (en) 2009-12-11
DE60331114D1 (de) 2010-03-11
US20070179187A1 (en) 2007-08-02
TW200404068A (en) 2004-03-16
CY1107184T1 (el) 2012-10-24
CY2015029I2 (el) 2016-04-13
RU2329264C9 (ru) 2009-04-20
SG164279A1 (en) 2010-09-29
FR15C0047I1 (pl) 2015-08-28
ATE494284T1 (de) 2011-01-15
US20030216437A1 (en) 2003-11-20
DE60317493D1 (en) 2011-01-13
ECSP045368A (es) 2005-01-03
WO2003089428A1 (en) 2003-10-30
JP4558331B2 (ja) 2010-10-06
DE60317493T2 (de) 2008-09-18
CN1659162B (zh) 2011-08-31
EP2065384A1 (en) 2009-06-03
ES2297150T7 (es) 2012-03-16
SI1495018T1 (sl) 2008-04-30
US7713999B2 (en) 2010-05-11
RU2004133375A (ru) 2005-07-10
CA2482858C (en) 2010-11-30
ES2297150T3 (es) 2008-05-01
BRPI0309309B1 (pt) 2018-09-04
EP2065384B1 (en) 2011-01-05
CY1111363T1 (el) 2015-08-05
BRPI0309309B8 (pt) 2021-05-25
NL300746I1 (pl) 2016-01-21
ES2338171T3 (es) 2010-05-04
HK1123302A1 (en) 2009-06-12
EP1495018B1 (en) 2007-11-14
TWI343919B (en) 2011-06-21
JP2010132710A (ja) 2010-06-17
SI2065384T1 (sl) 2011-05-31
AU2003221932A1 (en) 2003-11-03
MXPA04010308A (es) 2005-02-03
DE60335679D1 (de) 2011-02-17
FR15C0047I2 (fr) 2016-05-06
IL164585A0 (en) 2005-12-18
NO330500B1 (no) 2011-05-02
CA2482858A1 (en) 2003-10-30
US7304078B2 (en) 2007-12-04
NL300746I2 (pl) 2016-01-21
CY2015029I1 (el) 2016-04-13
EP2062890B1 (en) 2011-01-05
EP1982984A3 (en) 2008-10-29
CN1659162A (zh) 2005-08-24
ES2357876T3 (es) 2011-05-03
RU2329264C2 (ru) 2008-07-20
KR20040099441A (ko) 2004-11-26

Similar Documents

Publication Publication Date Title
LU92759I2 (en) Vorapaxar ou son sel solvat pharmacologiquement admissible
IL165841A0 (en) Mchir antagonists
GB0303210D0 (en) Early entry
GB0403532D0 (en) Early entry
EP1500622A4 (en) LIFT WITHOUT MACHINE ROOM
PL376509A1 (pl) Antagoniści IL-15
AP2004003119A0 (en) Substituted hydroxyethylamines
GB2395048B (en) Interface devices
AU153894S (en) Planer
GB0207015D0 (en) Interface
GB0211257D0 (en) Novel heterocycles
AU2003300904A8 (en) Antagonists for human prolactin
SI1487778T1 (sl) Substituirani 4-aminocikloheksanoli
EP1580045A4 (en) UPPER FASTENING
GB0209608D0 (en) Early entry
IL166740A0 (en) Substituted heterocyclylpyrimidines
AU2003268504A8 (en) Whale-safe rope
GB0317960D0 (en) Early entry
GB0209989D0 (en) Novel heterocycles
GB0414710D0 (en) Thyristor
EP1528032A4 (en) LIFT
IL162534A0 (en) Novel alkansulfonamides as endotheline antagonists
GB0215389D0 (en) Receptor
GB0228658D0 (en) Planer
TW543649U (en) Screw-style elevator